{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T20:00:52Z","timestamp":1792526452224,"version":"4.5.0"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"15","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["JAHA"],"published-print":{"date-parts":[[2021,8,3]]},"abstract":"<jats:sec xml:lang=\"en\">\n            <jats:title>Background<\/jats:title>\n            <jats:p xml:lang=\"en\">Patients with recurrent pericarditis (RP) may develop complications, multiple recurrences, or inadequate treatment response. This study aimed to characterize disease burden and unmet needs in RP.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec xml:lang=\"en\">\n            <jats:title>Methods and Results<\/jats:title>\n            <jats:p xml:lang=\"en\">This retrospective US database analysis included newly diagnosed patients with RP with \u226524\u00a0months of continuous history following their first pericarditis episode. RP was defined as \u22652 pericarditis episodes \u226528\u00a0days apart. Some patients had \u22652 recurrences, while others had a single recurrence with a serious complication, ie, constrictive pericarditis, cardiac tamponade, or a large pericardial effusion with pericardiocentesis\/pericardial window. Among these patients with multiple recurrences and\/or complications, some had features relating to treatment history, including long\u2010term corticosteroid use (corticosteroids started within 30\u00a0days of flare, continuing \u226590 consecutive days) or inadequate treatment response (pericarditis recurring despite corticosteroids and\/or colchicine, or other drugs [excluding NSAIDs] within 30\u00a0days of flare, or prior pericardiectomy). Patients (N=2096) had hypertension (60%), cardiomegaly (9%), congestive heart failure (17%), atrial fibrillation (16%), autoimmune diseases (18%), diabetes mellitus (21%), renal disease (20%), anxiety (21%), and depression (14%). Complications included pericardial effusion (50%), cardiac tamponade (9%), and constrictive pericarditis (4%). Pharmacotherapy included colchicine (51%), NSAIDs (40%), and corticosteroids (30%), often in combination. This study estimates 37\u00a0000 US patients with RP; incidence was 6.0\/100\u00a0000\/year (95% CI, 5.6\u20126.3), and prevalence was 11.2\/100\u00a0000 (95% CI, 10.6\u201211.7).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec xml:lang=\"en\">\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p xml:lang=\"en\">Patients with RP may have multiple recurrences and\/or complications, often because of inadequate treatment response and persistent underlying disease. Corticosteroid use is frequent despite known side\u2010effect risks, potentially exacerbated by prevalent comorbidities. Substantial clinical burden and lack of effective treatments underscore the high unmet need.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1161\/jaha.120.018950","type":"journal-article","created":{"date-parts":[[2021,7,21]],"date-time":"2021-07-21T08:59:46Z","timestamp":1626857986000},"update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":44,"title":["US Database Study of Clinical Burden and Unmet Need in Recurrent Pericarditis"],"prefix":"10.1161","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9240-8369","authenticated-orcid":false,"given":"Allan","family":"Klein","sequence":"first","affiliation":[{"name":"Cleveland Clinic Cleveland OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0794-3306","authenticated-orcid":false,"given":"Paul","family":"Cremer","sequence":"additional","affiliation":[{"name":"Cleveland Clinic Cleveland OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Apostolos","family":"Kontzias","sequence":"additional","affiliation":[{"name":"State University of New York Stonybrook New York NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Furqan","sequence":"additional","affiliation":[{"name":"Cleveland Clinic Cleveland OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Tubman","sequence":"additional","affiliation":[{"name":"Clearview Healthcare Partners Newton MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6675-660X","authenticated-orcid":false,"given":"Mike","family":"Roy","sequence":"additional","affiliation":[{"name":"Clearview Healthcare Partners Newton MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle Z.","family":"Lim\u2010Watson","sequence":"additional","affiliation":[{"name":"Kiniksa Pharmaceuticals Lexington MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Magestro","sequence":"additional","affiliation":[{"name":"Kiniksa Pharmaceuticals Lexington MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2014-306362"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv318"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2016.07.785"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.4065\/mcp.2010.0046"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.12763"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11739-018-1907-x"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2014.10.005"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.165.17.1987"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1208536"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2020.11.018"},{"key":"e_1_3_2_12_2","first-page":"99","article-title":"Recurrent pericarditis: current challenges and future prospects","volume":"7","author":"Dauphin C","year":"2016","unstructured":"Dauphin C, Merlin E, Chalard A. Recurrent pericarditis: current challenges and future prospects. Res Rep Clin Cardiol. 2016;7:99\u2013108.","journal-title":"Res Rep Clin Cardiol"},{"key":"e_1_3_2_13_2","volume-title":"PredniSONEReform prescribing information","author":"Roxane Laboratories, Inc.","year":"2012","unstructured":"Roxane Laboratories, Inc. PredniSONEReform prescribing information. November 2012."},{"key":"e_1_3_2_14_2","volume-title":"Orphan Drug Designation Amendment Application for Rilonacept","author":"Kiniksa Pharmaceuticals, Ltd","year":"2019","unstructured":"Kiniksa Pharmaceuticals, Ltd . Orphan Drug Designation Amendment Application for Rilonacept. Lexington, MA, 9 September 2019."},{"key":"e_1_3_2_15_2","volume-title":"Orphan drugs","author":"US FDA","unstructured":"US FDA . Orphan drugs. Available at: https:\/\/www.fda.gov\/media\/83372\/download. Accessed February 6, 2020."},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10741-013-9375-x"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10741-013-9382-y"},{"key":"e_1_3_2_18_2","volume-title":"Arcalyst (Rilonacept) Prescribing Information","year":"2021","unstructured":"Arcalyst (Rilonacept) Prescribing Information. London, UK: Kiniksa Pharmaceuticals (UK), Ltd.; 2021."},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2027892"}],"container-title":["Journal of the American Heart Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/JAHA.120.018950","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T11:47:39Z","timestamp":1715600859000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/JAHA.120.018950"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,3]]},"references-count":18,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2021,8,3]]}},"alternative-id":["10.1161\/JAHA.120.018950"],"URL":"https:\/\/doi.org\/10.1161\/jaha.120.018950","relation":{},"ISSN":["2047-9980"],"issn-type":[{"value":"2047-9980","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,3]]},"assertion":[{"value":"2020-10-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-04-14","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-07-21","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e018950"}}